Project Grant R41CA314908
Award Date 9/2/26
Completion Date 8/31/27
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newport Beach, CA 92660, USA
Similar Awards
- The National Cancer Institute awarded Vesicle Therapeutics Inc. $400,000 on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a targeted antisense oligonucleotide therapy for head and neck squamous cell carcinoma. Vesicle Therapeutics is synthesizing and evaluating a thiomorpholino-based antisense oligonucleotide designed to selectively inhibit the oncogenic STAT3A isoform while preserving the tumor-suppressive STAT3B isoform. The Phase I project...
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...
- The National Cancer Institute awarded The Broad Institute, Inc. $742,382 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate PTPN2 inhibition combined with STING agonism as a therapeutic approach to enhance immune-mediated control of head and neck squamous cell carcinoma. The research will examine the mechanism by which PTPN2 inhibition elevates STING levels in tumor cells and how the signaling pathways engaged by both therapies synergistically activate...
- The National Cancer Institute awarded Tiba Biotech LLC $399,300 on September 10, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted delivery of enhanced self-amplifying RNA encoding tumor antigens to the spleen for cancer immunotherapy. Tiba Biotech will combine proprietary enhanced self-amplifying RNA (esRNA) technology with spleen-targeting biodegradable nanoparticles based on molecularly defined dendritic structures to deliver tumor antigen to...
- The National Cancer Institute awarded $400,000 to Dauntless Biotherapeutics, Inc. on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop CD155-targeted antibody-drug conjugates for metastatic and triple-negative breast cancer. The project advances therapeutic candidates that combine direct tumor cytotoxicity with restoration of anti-tumor immunity. CD155 is expressed in over 60% of breast cancers, including triple-negative, HER2-positive, and HER2-low...
- The National Cancer Institute awarded Lipo-Immuno TECH LLC $348,352 on August 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a C18-ceramide analog drug targeting head and neck squamous cell carcinoma. The recipient is developing LCL768, a first-in-class compound that conjugates C18-ceramide with pyridinium to selectively accumulate in HNSCC mitochondria, bind LC3B, and recruit autophagosomes, with selenite included to induce DRP1 activation and lethal mitophagy....
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...
- The National Cancer Institute awarded Tezcat Biosciences, Inc., $399,855 on August 18, 2026, for tumor-targeted delivery of radio and chemotherapy in pancreatic cancer under the Cancer Treatment Research program (CFDA 93.395). Tezcat is developing a dual-payload drug candidate, TZT-102, that exploits macropinocytosis—a nutrient scavenging process overexpressed in mutant RAS pancreatic ductal adenocarcinoma cells—to deliver intracellular cytotoxic and radiotherapeutic agents. The compound...
- The National Cancer Institute awarded Seak Therapeutics, LLC $399,981 on September 19, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop SEAK193, a potent antimitotic agent designed to treat breast cancer brain metastasis. The work encompasses Phase 1 de-risking of SEAK193 as a single agent to assess its viability as a clinical candidate for treating breast cancer brain metastases, as well as brain metastases from lung cancer and melanoma and primary brain tumors...
- The National Cancer Institute awarded Riboscience LLC $306,739 on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to identify the most effective inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) for hepatocellular carcinoma treatment. The research aims to improve outcomes for liver cancer patients by evaluating second-generation ENPP1 inhibitors in hepatocellular carcinoma models. ENPP1 degrades cyclic GMP-AMP, a messenger molecule that...